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Stable gadolinium (III) chelates are nowadays routinely used as contrast agents 
for magnetic resonance imaging (MRI). Their noncovalent binding to Human 
Serum Albumin (HSA) has shown to improve their efficacy. Noncovalent 
interactions lead to complex formation that can be  quantified by several 
techniques usually tedious and time consuming. In this study, electrospray-
ionization (ESI) mass spectrometry was used to investigate the interaction 
between HSA and several gadolinium (III) complexes. The results were 
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compared to those obtained in liquid phase. Four gadolinium complexes were 
investigated: Gd-DTPA 1, Gd-C4Me-DTPA 2, Gd-EOB-DTPA 3, and MP-2269 
4. The relaxometry study shows that complexes 1 and 2 have no significant 
affinity for HSA, while 3 and 4 show increasing affinities for the protein. By ESI-
MS, 1:1 and 1:2 complexes between HSA and MP-2269 were detected for a 
twofold excess of the contrast agent, whereas a ligand/protein molar ratio of 4/1 
was necessary to observe a 1:1 stoichiometry for Gd-EOB-DTPA, an 
observation which is in good agreement with the known weaker affinity of the 
contrast agent for the protein. At a 4-fold molar excess, no supramolecular 
complex was observed for Gd-DTPA 1 and Gd-C4Me-DTPA 2. A tenfold molar 
excess was necessary to detect a 1:1 complex, confirming the very weak affinity 
of these contrast agents for HSA. 
 
Introduction 
Contrast agents for magnetic resonance imaging (MRI) are compounds which 
are able to enhance the contrast of the image by altering the water proton 
longitudinal (T1) and/or transverse (T2) relaxation times of the surrounding 
tissues(1,2). Stable gadolinium chelates are widely used because of the 
physicochemical properties of this lanthanide (seven unpaired electrons,  nine 
coordination sites and favorable electronic relaxation time). The complexation of 
this rare earth ion with an organic ligand like a polycarboxylic acid is necessary 
to minimise its toxicity but reduces to some extent its efficacy as the active core 
of the contrast agent. Through their action on the relaxation time T1, these 
paramagnetic complexes induce an increase of the MR signal intensity; 
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consequently, areas of the body containing those contrast agents will appear 
brighter in the MR image.  
When properly designed, these complexes are able to bind noncovalently to 
endogenous macromolecules.  Such interactions reduce the molecular mobility 
of the complex , leading  to a better modulation of the magnetic interactions 
between the unpaired electrons of the paramagnetic ion and the water protons 
and therefore to an improvement of the efficiency (relaxivity) of the agents(3).   
On the other hand, binding to blood proteins prolongs the vascular residence 
time of the contrast agents, a situation which is favorable to angiography and 
perfusion imaging(4).  
Human serum albumin (HSA, calculated molecular weight from the sequence 
66,437 Da(5)) is one of the proteins targeted by magnetic resonance agents 
because it is a large globular protein known to constitute about 4.5% of the 
plasma and to bind a large variety of molecules. The binding of a drug to this 
protein reduces its renal excretion rate and extends its blood half-life.  
The commercial contrast agent Gd-DTPA 1 or Magnevist® (Schering, Germany) 
has no significant affinity for HSA but some of its derivatives can bind 
noncovalently to the protein. For example, the Gd (III) complex of 4-
pentylbicyclo[2.2.2]octane-1-carboxyldi-L-aspartyllysine-derived DPTA, known 
as MP-2269 4, (figure1) shows by proton relaxometry a high affinity for serum 
albumin and by imaging an excellent vascular enhancement(6,7,8). Gd-(S)-EOB-
DTPA 3 [(4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxymethyl)-3,6,9-triazaun-
decanedioic acid, gadolinium complex] designed as a hepatocyte agent is also 
known for its moderate noncovalent binding to HSA(9).  
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Specific noncovalent binding is a driving force in the context of tissue-specific 
molecular imaging. It is therefore highly important to estimate the affinity of a 
contrast agent with respect to its target molecule. Such noncovalent interactions 
can be quantified by several techniques which are usually tedious and time 
consuming, like equilibrium dialysis, ultrafiltration, chromatography, 
ultracentrifugation(10) and relaxometry. Today, mass spectrometry is emerging 
as a powerful tool for studying noncovalent interactions including protein 
interactions with inhibitors, cofactors, metal ions, or other peptides(11,12,13). From 
the measurement of the molecular mass of the entire complex, and knowing the 
mass of the individual binding partners, the stoichiometry can be derived. 
Electrospray ionization mass spectrometry (ESI-MS) can thus provide 
complementary data to those obtained by more traditional techniques. In this 
work, we apply ESI-MS to study the noncovalent interactions between human 
serum albumin (HSA) and the contrast agents 1-4, known for their diverse 
affinities for the protein. It has to be mentioned that among those complexes, 
only 1 and 3 are commercially available for clinical use.  
 
Materials and Methods 
Electrospray mass spectra were obtained on a Q-tof 2 (Micromass, Manchester, 
UK). The nanospray source was operated in the positive ion mode at a capillary 
voltage of 1.4 kV. Samples, dissolved in ammonium acetate (100 mM), were 
injected at a flow rate of a few nL/min with needles. Each spectrum is the sum 
of approx. 400 scans. The raw spectra were then baseline corrected before 
deconvolution, which was performed using the program MaxEnt1 TM.   
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Non defatted HSA A-1653, purchased from Sigma (Bornem, Belgium), was 
desalted by five dilution-concentration steps using Microcon YM-10 from 
Millipore (Brussels, Belgium). The protein concentration was measured 
spectrophotometrically (UV 280 nm) (8452A diode array spectrophotometer 
Hewlett-Packard, Brussels, Belgium). The concentration of albumin samples 
injected in the mass spectrometer was 5 µM. 
Gd-C4-Me-DTPA 2 was prepared as described recently(14), Gd-DTPA 1 and Gd-
EOB-DTPA 3 were provided by Schering AG (Berlin, Germany), and MP-2269 4 
was provided by Mallinckrodt (Saint-Louis, USA) (figure 1). All experiments 
were done with a fixed HSA concentration (5 µM), while the concentration of the 
ligand was varied between 5 and 50 µM, depending on its affinity towards the 
protein. 
Results and Discussion 
Human serum albumin, the target protein in our study, is the major proteinic 
component of blood plasma with a molecular weight of about 66437 Da. It 
contains 585 aminoacids, 35 of which are cystein residues involved in 17 
disulphide bridges. Some publications concerning the applications of 
electrospray ionisation mass spectrometry to biological compounds have shown 
spectra of human and bovine serum albumin recorded on positive mode with 
very high charge states indicating a partial denaturation of the protein(15-19). 
In order to use mass spectrometry as a complementary technique to study the 
affinity of contrast agents towards human serum albumin, it is important to find 
experimental conditions that keep the protein in its native state and limit the 
formation of adducts with the macromolecule. The protein was thus dissolved in 
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a solution of ammonium acetate. In this solution, four charge states ranging 
from 15+ to 18+ were observed, in agreement with a molecular weight of 66,540 
Da. The molecular weight of HSA, computed from SwissProt entry P02768 
using the ExPASy tool “pI/MW calculator” (assuming no modifications) is 
66472.21. Thus, ammonium acetate disturbs only slightly the conformation of 
human serum albumin. However, it has to be mentioned that the protein shows 
a very weak mass spectrometric response.  
We explored the effect of the source temperature and the cone voltage on the 
spectra of HSA in ammonium acetate. From 65°C to 125°C at a high cone 
voltage (180V), the mass spectrum does not show an additional peak but the 
signal intensities are slightly increased at high temperature due to a better 
desolvation. The peak with the maximum intensity is always the one 
corresponding to the charge state 16+. As expected, a decrease of cone 
voltage causes a significant increase in the width of each peak, from about 30 
m/z for a cone voltage of 180 volts to about 100 m/Z for a cone voltage of 60 
volts at low temperature. We decided thus to record all spectra at a cone 
voltage of 180 volts and a source temperature of 80°C in order to obtain a good 
signal intensity as well as a good spectral resolution.  
The first contrast agent tested, MP-2269 4, is known to interact by noncovalent 
binding with HSA in solution. When the concentrations of HSA and MP-2269 
were equal  (5 µM), signals corresponding to a complex between the protein 
and one molecule of contrast agent were observed, in addition to the peaks 
corresponding to free HSA. When the MP-2269 4 concentration was twice the 
concentration of the target, a new signal corresponding to a stoichiometry 2:1 
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clearly appeared. When the concentration of contrast agent was increased until 
20 µM, this stoichiometry was preserved and the intensities of the peaks of the 
free protein decreased. For each massive, the intensity of the peak  of the 
complex between the protein and one ligand was the most important (figure 2). 
Different to the spectrum of HSA alone, the charge state showing the highest 
intensity was 17+.  
For Gd-EOB-DTPA 3, which is known to have a moderate affinity for HSA, a 
fourfold molar excess was necessary to observe a signal corresponding to a 
complex with a 1:1 stoichiometry. When the concentration of Gd-EOB-DTPA 3 
was brought to a ten molar excess, the stoichiometry reached a maximum of 
three molecules of contrast agents bound to the protein (figure 3). As observed 
above with MP-2269, the charge state showing the highest intensity was 17+. 
In order to confirm that the detection in the gas phase reflects the behaviour 
observed in solution, we studied the affinity of Gd-DTPA 1, a contrast agent 
showing no affinity for HSA in solution. With ESI-MS, at least a tenfold molar 
excess was necessary to observe some association between Gd-DTPA and the 
protein (figure 4).  
Similarly, for Gd-C4Me-DTPA 2 a complex corresponding to one ligand bound to 
the protein was observed for a tenfold molar excess of ligand (figure 4). At lower 
ligand concentrations no complex peak could be detected. 
The relative intensities of the multiply charged ions from the various 
noncovalent complexes were compared. An excellent qualitative correlation was 
found with the binding constants known from solution studies, indicating that the 
results of the titration experiments carried out with the electrospray mass 
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spectrometry technique can be used for qualitative assessment of such 
interactions. 
In order to obtain quantitative information about the affinity of Gd-EOB-DTPA 3 
and MP-2269 4 for HSA, the peak heights of the various multiply charged ions 
of the free protein and of the protein-contrast agent complex were summed to 
evaluate the respective concentrations. This treatment was performed by using 
the program MaxEnt1TM (figure 5) which uses the maximum entropy method to 
reconstruct singly charged mass spectra from multiply charged ones. With this 
treatment, we could obtain the concentrations of the different species in gas 
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equation 2 
Where C1, C2 ,C3,… are the peak intensities of the different complexes, Pf is the 
peak intensity of the free protein and [P0] is the total concentration of protein in 
solution. 
Using the concentration values obtained by this procedure, an apparent 
association constant was calculated from the data of each solution assuming 
two identical binding sites, in agreement with earlier relaxometry studies. 
Apparent association constants of about 27000 M-1 and about 5000 M-1 were 
obtained (table 1) for MP-2269 4 and Gd-EOB-DTPA 3 respectively, following 




The advantages and disadvantages of ESI-MS are often discussed and 
compared to other biophysical methods for the investigation of noncovalent 
interactions. At present, soft ionisation mass spectrometry is increasingly used 
to analyse noncovalent complexes. The present study of the interaction 
between HSA and MRI contrast agent offers a previously unreported system 
confirming the versatility of electrospray mass spectrometry for the 
characterisation of noncovalent complexes. In fact, the study of interactions 
between HSA and MRI contrast agents by ESI-MS allowed a confirmation of 
their affinities for HSA. Thus, MP-2269 4 is the contrast agent which has the 
best affinity for the protein, followed by Gd-EOB-DTPA 3. 
For Gd-DTPA 1 and Gd-C4Me-DTPA 2, the titration experiment showed that it 
was necessary to reach a tenfold excess of ligand to observe peaks 
corresponding to a complex. These contrast agents have thus very low, if any, 
affinity for HSA. Another advantage of mass spectrometry is the direct 
information on stoichiometry. The number of ligands noncovalently bound to the 
macromolecule is easily determined. This certainly represents important 
information for the evaluation of the association constant that is not easily 
obtained by classical biophysical techniques. Thanks to its speed and 
sensitivity, electrospray mass spectrometry is a technique able to compete with 
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Figure 1: Structures of Gd-DTPA 1(MW=591)Gd-C4Me-DTPA 2(MW=605), Gd-












Figure 2: Electrospray spectra of HSA (5 µM) with MP-2269 at A: 5 µM, B: 10 
µM, C: 20 µM. D: Electrospray spectra of HSA without contrast agent. ∇ free 

































































































Figure 3: Electrospray spectra of HSA (5 µM) with Gd-EOB-DTPA at A: 20 µM, 




      
Figure 4: Electrospray spectra of HSA (5 µM) with Gd-DTPA and Gd-C4-Me-
DTPA at A: Gd-DTPA 20 µM, B: Gd-DTPA 50 µM, C: Gd-C4Me-DTPA 20 µM, 
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Figure 5: Procedure used for the quantitative processing of the mass spectra 


































5 4.12 0.79 0.09 0 4.03 26.7(2)  
 
10.0 (2) 
10 3.32 1.53 0.15 0 8.17 27.4 (2) 
20 2.73 1.38 0.89 0 16.8 27.4 (2) 






















20 4.39 0.37 0.24 0 19.2 4.8(2)  
0.772±0.195(1) 
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